Research

Filter by Region, Sector, or Focus
The UVA Licensing & Ventures Group helps discoveries reach their full potential in the marketplace. In 2018 there were 213 invention disclosures filed, 59 U.S. patents issued and 77 transactions with commercial partners. 
UVA professors and administrators secured a nearly $7.6 million contract from the Defense Advanced Research Projects Agency to detect broad-spectrum cyber threats almost immediately after they are launched.
PsiKick is utilizing revolutionary ultra-low-power technologies from the Universities of Virginia and Michigan to build completely self-powered sensing systems that do not require batteries, can be deployed nearly anywhere, and unlock new data stream
UVA Professor Shawn Russell helps those with disabilities take on skiing, proving that biomechanics research has real-life applications that can change lives for the better in Virginia and beyond.
PsiKick is utilizing revolutionary ultra-low-power technologies from the Universities of Virginia and Michigan to build completely self-powered sensing systems that do not require batteries, can be deployed nearly anywhere, and unlock new data stream
Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).
The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.
NSF funding will allow UVA Engineering’s Link Lab to develop a new program that will train graduate students to make discoveries and then translate that knowledge into new technologies, products and services.
Professor Gregory B. Fairchild is the first director of Northern Virginia operations for the University of Virginia.
UVA leaders celebrated the announcement of Amazon's decision to locate a major headquarters function in Virginia as a significant opportunity to increase our contributions to the state and to collaborate with additional Virginia universities to creat
Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).